
News and Publications
NEWS
07/18/2023
Arkuda Therapeutics to Present Update on ARKD-104, its First-in-Class Oral Development Candidate for the Treatment of Frontotemporal Dementia and other Neurodegenerative Disorders at the Alzheimer’s Association International Conference 2023
Study demonstrates ARKD-104 has excellent CNS drug-like properties, increases PGRN in the CNS of non-human primates a…
04/04/2023
Arkuda Therapeutics Strengthens Management Team to Support Ongoing Discovery and Translation to the Clinic
Duane Burnett, PhD, appointed Chief Technology Officer, Raymond Hurst, PhD, promoted to Senior Vice President, Head o…
02/09/2022
Arkuda Therapeutics Raises $64 Million Series B Financing to Advance Pipeline of Programs Targeting Lysosomal Biology to Treat Neurodegenerative Diseases
Funding to support progression of lead progranulin enhancer program into IND-enabling studies Small molecule platform…
PUBLICATIONS
07/18/2023
ARKD-104, A Potential Treatment of Frontotemporal Dementia and Other Neurodegenerative Disorders
Serena Hung, Raymond S. Hurst, Jean-François Blain, Christopher Holler, Angela Chen, Morgan Brand, Anna-Maria Alves,…
10/07/2021
DISCOVERY OF SMALL MOLECULES FOR THE TREATMENT OF PD-GBA
Natasha Khatri, Mary K. Wozniak, Jerusha K. Brendel, Anna-Maria Alves, Christopher J. Holler, James C. Lanter, Duane …
04/08/2020
DISCOVERY OF NOVEL SMALL MOLECULES FOR THE TREATMENT OF FTD-GRN
Christopher J. Holler, Angela Chen, Natasha Khatri, James C. Lanter, Ricardo L. Sanz, Jerusha K. Brendel, Mary Woznia…
MEDIA CONTACT
Lissette Steele
Verge Scientific Communications
lsteele@vergescientific.com
202.930.4762
